GMAB vs INSM
Genmab A/S and Insmed Incorporated, both Healthcare
Insmed Incorporated is the larger company at $21B against $16B. Over the past year GMAB returned +49% against +14% for INSM. Ryufin's sector-relative Smart Score puts GMAB ahead, 9/10 against 2/10.
| Figure | GMAB | INSM |
|---|---|---|
| Last close | $33.75 | $124 |
| Market cap | $16B | $21B |
| 1-year return | +49% | +14% |
| 5-year return | -25% | +415% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 2/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Genmab A/S
Revenue of $12B in H2 2024, net income $5.1B.
Insmed Incorporated
Revenue of $425M in Q2 2026, net income null. Its largest reported line is United States, 60% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.